HUMA PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

HUMA ▼ -26.99% at T+5d

NEUTRAL call ✗ call lost -26.99% · α vs SPY -25.83% · entry $1.13 → $0.8250

Next anchor: T+20d tomorrow

Last close $1.38 (close Jun 8) · +22.12% from $1.13 entry

Entry anchored
May 12, 03:59 PM ET
via Databento tick

T+1d

-11.50%

call -11.50% · α -12.28%

$1.00

settled 27d ago

T+5d

-26.99%

call -26.99% · α -25.83%

$0.8250

settled 21d ago

T+20d

—

call — · α —

—

tomorrow

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Humacyte reported Q1 2026 revenue of $0.5M (vs $1.5M consensus) and EPS of -$0.13 (vs -$0.12 consensus), a miss on both top and bottom lines. The company announced a 25% workforce reduction expected to save $14.3M in 2026, and highlighted upcoming interim Phase 3 hemodialysis data on June 11, 2026 as a key catalyst.

Actionable Insight

The stock will trade on the June 11 interim hemodialysis data readout — a positive result could drive significant upside given the $202M market cap. However, the revenue miss and ongoing cash burn (net cash used $2M in Q1) warrant caution. Monitor for supplemental BLA filing in H2 2026 if data is positive.

Key Facts

Q1 2026 product revenue $0.5M (29 units) vs $0.1M (5 units) in Q1 2025
EPS -$0.13 vs consensus -$0.12 (miss)
Revenue $0.5M vs consensus $1.5M (miss)
Net loss $17.6M vs net income $39.1M in Q1 2025 (driven by non-cash earnout liability change)
Workforce reduction of ~25% (45 employees) expected to save $14.3M in 2026
Restructuring charges of ~$0.8M expected in Q2 2026
Cash and equivalents $48.9M as of March 31, 2026
Top-line interim results from V012 Phase 3 hemodialysis study expected June 11, 2026
Purchase commitment of $1.475M from Saudi Arabia for clinical evaluation program
Appointed new Chief Commercial Officer and Chief Surgical Officer

Financial Impact

Revenue miss of ~$1M vs consensus; net loss of $17.6M; restructuring savings of $14.3M

revenueepsnet incomecash burnoperating expenses

Risk Factors

Revenue miss and EPS miss vs consensus
Ongoing net losses and cash burn
Dependence on positive Phase 3 hemodialysis data for next catalyst
Restructuring execution risk and potential further charges
Dilution risk from equity offerings (raised $23.3M from share sales in Q1 2026)

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

85% bullish (13 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3293828

6 reports for HUMA

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for HUMA — sortable, filterable
	Type				Now
May 20, 2026 20d ago	Insider Cluster NEUTRAL ★ 3/10	$1.02 $1.28	▲ +25.49%	▲ +23.89%	$1.38 (+35.29%)
May 13, 2026 27d ago	Press Release MIXED ★ 6/10	$1.13 $0.8250	▼ −26.99%	▼ −25.83%	$1.38 (+22.12%)
May 8, 2026 4w ago	Press Release NEUTRAL ★ 2/10	$1.06 $1.00	▼ −5.66%	▼ −7.12%	$1.38 (+30.19%)
Apr 21, 2026 7w ago	Press Release BULLISH ★ 7/10	$0.6590 $0.8480	▲ +28.68%	▲ +27.60%	$1.38 (+109.41%)
Mar 23, 2026 11w ago	Press Release NEUTRAL ★ 3/10	$0.8500 $0.5750	▼ −32.35%	▼ −28.79%	$1.38 (+62.35%)
Mar 19, 2026 11w ago	Press Release MIXED ★ 5/10	$0.8540 $0.7780	▼ −8.90%	▼ −6.69%	$1.38 (+61.59%)

US Market Status

Market Closed — Opens in 7h 12m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access